Increased bone metabolism in a patient undergoing long-term rhG-CSF treatment for idiopathic acquired neutropenia.
Recombinant human granulocyte colony-stimulating factor (rhG-CSF) has been used mainly for treatment of chemotherapy-induced neutropenia. The reported side effects were of minor importance. We describe a case of long-term treatment with rhG-CSF, in which we observed enhanced bone remodeling.